Design, synthesis, in vitro and in vivo evaluation, and structure-activity relationship (SAR) discussion of novel dipeptidyl boronic acid proteasome inhibitors as orally available anti-cancer agents for the treatment of multiple myeloma and mechanism stud
Keywords: نیمه حداکثر غلظت مهاری; SAR; structureactivity relationship; UPP; ubiquitinproteasome pathway; FDA; Food and Drug Administration; ATP; Adenosine triphosphate; CP; core particle; RP; regulatory proteasome; C-L; caspase-like; T-L; trypsin-like; CT-L; chymotrypsin-like; EDCI; 1-eth